Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously announced, the board of directors (the "Board") of Blonder Tongue Laboratories, Inc. (the "Company"), based on the recommendation of the Compensation Committee of the Board, approved certain changes to the compensation to be received by directors. Those changes involved the issuance of options to purchase shares of the Company's common stock to directors for their service on the Board and committees of the Board in lieu of the combination of cash payments and common stock grants that had comprised the compensation package for directors previously. The Board also indicated that it would reevaluate director compensation practices in advance of July 1, 2022. In connection with the reevaluation, the Board, based on the recommendation of the Compensation Committee of the Board, approved the grant of options to purchase 20,000 shares of the Company's common stock to each of the directors. These grants are in lieu of any cash compensation that would otherwise be payable to directors during the remainder of 2022. The grant date is June 1, 2022, the options will vest on October 1, 2022 and have a term of 10 years from the grant date and an exercise price of $0.39, which is equal to the closing price of the Company's common stock on NYSE American on June 1, 2022.


                                       1

© Edgar Online, source Glimpses